Gambro divests the Excorim immunoadsorption business

12/14/1999 3:04 AM EST

Stockholm, Sweden - Gambro AB (Stockholm Stock Exchange: GAMBaST,
GAMBbST), a leading international medical technology and healthcare com-
pany, today announced that it has agreed to sell the Excorim immunoadsorp-
tion business to Fresenius Hemocare effective January 24, 2000. Excorim is
an operating unit of COBE BCT, a subsidiary of Gambro. In 1998 Excorim had
sales of about SEK 30 M (USD 3.4 M).

Excorim is specialized in immunoadsorption with the principal products
immunoadsorption columns and equipment. The divestiture of Excorim is part
of the strategic focusing of the COBE BCT business to blood bank
technology and therapeutic specialties.

For further information please contact:
Ed Wood, President of COBE BCT, tel. +1-303-232-6800
Bengt Modéer, Senior Vice President, Corporate Communications, tel. +46-8-
613 65 00,
+46-70-513 65 33
Anna Augustson, European Investor Relations Manager, tel. +46-8-613 65 35,
+46-70-513 65 34

Gambro is a global medical technology and healthcare company with leading
positions in renal care - services and products - and blood component
technology (BCT). Gambro is one of the leading providers of kidney
dialysis services in the world. Gambro treats about 43,200 patients in 581
clinics worldwide. Renal care products comprise dialyzers, dialysis
machines, blood lines and dialysis concentrates. BCT includes products for
the separation and handling of blood components. The group, with revenue
of approximately SEK 18 billion (USD 2.2 billion), has approximately
17,000 employees in some 40 countries.